Treatment of Pituitary Gigantism with the Growth Hormone Receptor Antagonist Pegvisomant-Reference-Cited by-同舟云学术

Treatment of Pituitary Gigantism with the Growth Hormone Receptor Antagonist Pegvisomant

Published:2008-08-01 Issue:8 Volume:93 Page:2953-2956
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Goldenberg Naila¹,Racine Michael S.¹,Thomas Pamela²,Degnan Bernard³,Chandler William⁴¹,Barkan Ariel⁴¹

Affiliation:

1. Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine (N.G., M.S.R., W.C., A.B.), University of Michigan Medical Center, Ann Arbor, Michigan 48109

2. Department of Pediatric Endocrinology (P.T.), Lutheran Children’s Hospital, Fort Wayne, Indiana 46804

3. Department of Pediatric Endocrinology (B.D.), St. John’s Hospital, Detroit, Michigan 48236

4. the Department of Neurosurgery (W.C., A.B.), University of Michigan Medical Center, Ann Arbor, Michigan 48109

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/93/8/2953/9052298/jcem2953.pdf

Reference17 articles.

1. Gigantism

2. The acromegaly gigantism syndrome. Report of four cases treated surgically.;Zampieri;Surg Neurol,1983

3. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.;Cozzi;J Clin Endocrinol Metab,2006

4. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.;Trainer;N Engl J Med,2000

5. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12 year old girl.;Rix;Eur J Endocrinol,2005

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07

2. Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism;Frontiers in Endocrinology;2024-02-28

3. Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases;Nature Reviews Endocrinology;2024-02-09

4. Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP);Annales d'Endocrinologie;2023-12

5. Chromosomal microdeletion leading to pituitary gigantism through hormone-gene overexpression;Human Molecular Genetics;2023-04-18